Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- Trading 90% below Graham Number ($68.10) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -44.8%
- Revenue declining 78% annually
Kyntra Bio, Inc. - Common Stock (KYNB) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $27 million . Key value metrics: P/E ratio 0.1, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Kyntra Bio, Inc. - Common Stock — Fundamental Analysis Summary
Kyntra Bio, Inc. - Common Stock (KYNB) is trading 90% below its Graham Number of $68.10 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 0.1x.
On financial health, KYNB shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -44.8% (sector average: -19.8%).
StockPik's composite Value Score for KYNB is 87/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
KYNB reports a high gross margin of 89.2% (sector average: 33.5%) and a negative operating margin of -95.5%.
KYNB shows revenue declining at 78% year-over-year, with earnings growing at 486%.